From mice to humans: developments in cancer immunoediting

Hallmarks of Cancer: The Next Generation

Hanahan, D., & Weinberg, R. A. (2011) · Cell · doi:10.1016/j.cell.2011.02.013 · Cited by 66,590

PD-1 and PD-L1 Immune Checkpoint Blockade to Treat Breast Cancer

Hartkopf, A. D., Taran, F., Wallwiener, M., Walter, C. B., Krämer, B., Grischke, E., & Brucker, S. Y. (2016) · Breast Care · doi:10.1159/000453569 · Cited by 30,989

Improved Survival with Ipilimumab in Patients with Metastatic Melanoma

Hodi, F. S., O'Day, S. J., McDermott, D. F., Weber, R. W., Sosman, J. A., Haanen, J. B., Gonzalez, R., Robert, C., Schadendorf, D., Hassel, J. C., et al. (2010) · New England Journal of Medicine · doi:10.1056/nejmoa1003466 · Cited by 15,155

The blockade of immune checkpoints in cancer immunotherapy

Pardoll, D. M. (2012) · Nature Reviews Cancer · doi:10.1038/nrc3239 · Cited by 13,838

Safety, activity, and immune correlates of anti–PD-1 antibody in cancer

Topalian, S. L., Hodi, F. S., Brahmer, J. R., Gettinger, S. N., Smith, D. C., McDermott, D. F., Powderly, J. D., Carvajal, R. D., Sosman, J. A., Atkins, M. B., et al. (2012) · New England Journal of Medicine · doi:10.1056/nejmoa1200690 · Cited by 12,628

PD-1 Blockade in Tumors with Mismatch-Repair Deficiency

Le, D. T., Uram, J. N., Wang, H., Bartlett, B. R., Kemberling, H., Eyring, A. D., Skora, A. D., Luber, B. S., Azad, N. S., Laheru, D., et al. (2015) · New England Journal of Medicine · doi:10.1056/nejmoa1500596 · Cited by 9,377

Safety and activity of anti-PD-L1 antibody in patients with advanced cancer

Brahmer, J. R., Tykodi, S. S., Chow, L. Q. M., Hwu, W.-J., Topalian, S. L., Hwu, P., Drake, C. G., Camacho, L. H., Kauh, J., Odunsi, K., et al. (2012) · New England Journal of Medicine · doi:10.1056/nejmoa1200694 · Cited by 7,945

Cancer Genome Landscapes

Vogelstein, B., Papadopoulos, N., Velculescu, V. E., Zhou, S., Diaz, L. A., & Kinzler, K. W. (2013) · Science · doi:10.1126/science.1235122 · Cited by 7,863

Intratumor Heterogeneity and Branched Evolution Revealed by Multiregion Sequencing

Gerlinger, M., Rowan, A. J., Horswell, S., Larkin, J., Endesfelder, D., Gronroos, E., Martinez, P., Matthews, N., Stewart, A., Tarpey, P., et al. (2012) · New England Journal of Medicine · doi:10.1056/nejmoa1113205 · Cited by 7,774 · cited 1×

PD-1 blockade induces responses by inhibiting adaptive immune resistance

Tumeh, P. C., Harview, C. L., Yearley, J. H., Shintaku, I. P., Taylor, E. J. M., Robert, L., Chmielowski, B., Spasic, M., Henry, G., Ciobanu, V., et al. (2014) · Nature · doi:10.1038/nature13954 · Cited by 6,609

Bioinspired magnetic nanocomplexes amplifying STING activation of tumor-associated macrophages to potentiate cancer immunotherapy

Li, T., Song, R., Sun, F. Z., Saeed, M., Guo, X., Ye, J., Chen, F., Hou, B., Zhu, Q., Wang, Y., et al. (2022) · Nano Today · doi:10.1016/j.nantod.2022.101400 · Cited by 34

Immunotherapy as an Option for Cancer Treatment

Rusch, T., Bayry, J., Werner, J., Shevchenko, I., & Bazhin, A. V. (2017) · Archivum Immunologiae et Therapiae Experimentalis · doi:10.1007/s00005-017-0491-5 · Cited by 35

The new progress in cancer immunotherapy

Shimu, A. S., Wei, H.-X., Li, Q., Zheng, X., & Li, B. (2022) · Clinical and Experimental Medicine · doi:10.1007/s10238-022-00887-0 · Cited by 36

Tumor-infiltrating lymphocytes in melanoma: from prognostic assessment to therapeutic applications

Bida, M., Miya, T. V., Hull, R., & Dlamini, Z. (2024) · Frontiers in Immunology · doi:10.3389/fimmu.2024.1497522 · Cited by 34

Immune Cell Metabolism in Tumor Microenvironment

Li, Y., Wan, Y. Y., & Zhu, B. (2017) · Advances in experimental medicine and biology · doi:10.1007/978-94-024-1170-6_5 · Cited by 34

Ferroptosis-related genes identify tumor immune microenvironment characterization for the prediction of prognosis in cervical cancer

Yang, X., Yin, F., Liu, Q., Ma, Y., Zhang, H., Guo, P., Wen, W., Guo, X., Wu, Y., Yang, Z., et al. (2021) · Annals of Translational Medicine · doi:10.21037/atm-21-6265 · Cited by 32

Microenvironmental regulation of the progression of oral potentially malignant disorders towards malignancy

Ai, R., Yan, T., Hao, Y., Jiang, L., Dan, H., Ji, N., Zeng, X. Y., Zhou, Y. J., & Chen, Q. (2017) · Oncotarget · doi:10.18632/oncotarget.20312 · Cited by 35

The next level of 3D tumour models: immunocompetence

Nyga, A., Neves, J. B., Stamati, K., Loizidou, M., Emberton, M., & Cheema, U. (2016) · Drug Discovery Today · doi:10.1016/j.drudis.2016.04.010 · Cited by 33

The clinical implications of immunogenomics in colorectal cancer: A path for precision medicine

Riley, J. M., Cross, A. W., Paulos, C. M., Rubinstein, M. P., Wrangle, J. M., & Camp, E. R. (2018) · Cancer · doi:10.1002/cncr.31214 · Cited by 31

The Roles of Immune Cells in Gastric Cancer: Anti-Cancer or Pro-Cancer?

Sukri, A., Hanafiah, A., & Kosai, N. R. (2022) · Cancers · doi:10.3390/cancers14163922 · Cited by 32

Endoplasmic Reticulum Stress in Cancer

Zhou, R., Wang, W., Li, B., Zhu, L., Huang, J., & Li, X. (2025) · MedComm · doi:10.1002/mco2.70263 · Cited by 39

Influence of Innate Immunity on Cancer Cell Stemness

Pastò, A., Consonni, F. M., & Sica, A. (2020) · International Journal of Molecular Sciences · doi:10.3390/ijms21093352 · Cited by 33

Coevolution of Leukemia and Host Immune Cells in Chronic Lymphocytic LeukemiaPreprint

Purroy, N., & Wu, C. J. (2017) · Cold Spring Harbor Perspectives in Medicine · doi:10.1101/cshperspect.a026740 · Cited by 33

Periodontal pathogens and cancer development

Zhou, Y., Meyle, J., & Groeger, S. E. (2024) · Periodontology 2000 · doi:10.1111/prd.12590 · Cited by 29

Relationship between immune checkpoint proteins, tumour microenvironment characteristics, and prognosis in primary operable colorectal cancer

Al-Badran, S. S. F., Grant, L., Campo, M. V., Inthagard, J., Pennel, K. A. F., Quinn, J. A., Konanahalli, P., Hayman, L., Horgan, P. G., McMillan, D., et al. (2020) · The Journal of Pathology Clinical Research · doi:10.1002/cjp2.193 · Cited by 29

Improved cancer immunotherapy strategies by nanomedicine

Guo, S., Feng, J., Li, Z., Yang, S., Qiu, X., Xu, Y., & Shen, Z. (2022) · Wiley Interdisciplinary Reviews Nanomedicine and Nanobiotechnology · doi:10.1002/wnan.1873 · Cited by 29

Immune microenvironment of cervical cancer and the role of IL-2 in tumor promotion

Trujillo-Cirilo, L., Weiss‐Steider, B., Vargas-Ángeles, C. A., Corona-Ortega, M. T., & Rangel-Corona, R. (2023) · Cytokine · doi:10.1016/j.cyto.2023.156334 · Cited by 29

Modeling tumor immunity of mouse glioblastoma by exhausted CD8+ T cells

Nakashima, H., Alayo, Q. A., Penaloza‐MacMaster, P., Freeman, G. J., Kuchroo, V. K., Reardon, D. A., Fernández, S., Caligiuri, M. A., & Chiocca, E. A. (2018) · Scientific Reports · doi:10.1038/s41598-017-18540-2 · Cited by 29

Immunotherapy for Advanced Melanoma: Future Directions

Valpione, S., & Campana, L. G. (2016) · Immunotherapy · doi:10.2217/imt.15.111 · Cited by 29

Angiogenesis-Related Immune Signatures Correlate With Prognosis, Tumor Microenvironment, and Therapeutic Sensitivity in Hepatocellular Carcinoma

Yang, Y., Wu, G., Li, Q., Zheng, Y., Liu, M., Zhou, L., Chen, Z., Wang, Y., Guo, Q., Ji, R., et al. (2021) · Frontiers in Molecular Biosciences · doi:10.3389/fmolb.2021.690206 · Cited by 27

PTEN at the interface of immune tolerance and tumor suppression

Brandmaier, A., Hou, S., Demaria, S., Formenti, S. C., & Shen, W. H. (2017) · Frontiers in Biology · doi:10.1007/s11515-017-1443-5 · Cited by 27

Immune cytolytic activity is associated with reduced intra-tumoral genetic heterogeneity and with better clinical outcomes in triple negative breast cancer.

Oshi, M., Kawaguchi, T., Yan, L., Peng, X., Qi, Q., Tian, W., Schulze, A. K., McDonald, K.-A., Narayanan, S., Young, J. S., et al. (2021) · PubMed · Cited by 28

Overcoming Immunosuppression and Pro-Tumor Inflammation in Lung Cancer with Combined IL-1β and PD-1 Inhibition

Lee, J. M., Tsuboi, M., Kim, E. S., Mok, T. S. K., & Garrido, P. (2022) · Future Oncology · doi:10.2217/fon-2021-1567 · Cited by 28

Natural biomolecules and derivatives as anticancer immunomodulatory agents

Bernitsa, S., Dayan, R., Stephanou, A., Tzvetanova, I. D., & Patrikios, I. S. (2023) · Frontiers in Immunology · doi:10.3389/fimmu.2022.1070367 · Cited by 29

Radiolabelling and preclinical characterization of 89Zr-Df-radiolabelled bispecific anti-PD-L1/TGF-βRII fusion protein bintrafusp alfa

Burvenich, I. J. G., Goh, Y. W., Guo, N. Y., Gan, H. K., Rigopoulos, A., Cao, D., Liu, Z., Ackermann, U., Wichmann, C. W., McDonald, A. F., et al. (2021) · European Journal of Nuclear Medicine and Molecular Imaging · doi:10.1007/s00259-021-05251-0 · Cited by 27

Understanding the Immune-Stroma Microenvironment in B Cell Malignancies for Effective Immunotherapy

Apollonio, B., Ioannou, N., Papazoglou, D., & Ramsay, A. G. (2021) · Frontiers in Oncology · doi:10.3389/fonc.2021.626818 · Cited by 27

Tumor Secretome to Adoptive Cellular Immunotherapy: Reduce Me Before I Make You My Partner

Etxebeste-Mitxeltorena, M., del Rincón-Loza, I., & Martín-Antonio, B. (2021) · Frontiers in Immunology · doi:10.3389/fimmu.2021.717850 · Cited by 26

Intraepithelial CD8+ lymphocytes as a predictive diagnostic biomarker for the remission of oral lichen planus

Enomoto, A., Sato, E., Yasuda, T., Isomura, T., Nagao, T., & Chikazu, D. (2017) · Human Pathology · doi:10.1016/j.humpath.2017.12.008 · Cited by 26

Development of cancer immunotherapy based on PD-1/PD-L1 pathway blockade

Zhang, M., Liu, K., & Wang, M. (2019) · RSC Advances · doi:10.1039/c9ra04590b · Cited by 26

Immune checkpoint expression on peripheral cytotoxic lymphocytes in cervical cancer patients: moving beyond the PD-1/PD-L1 axis

Ibarra, F. S., Alejandre-González, A. G., Ortiz‐Lazareno, P. C., Bastidas‐Ramírez, B. E., Zepeda‐Moreno, A., Téllez‐Bañuelos, M. C., Banu, N., Carrillo-Garibaldi, Ó. J., Alvarado, A. C., Bueno‐Topete, M. R., et al. (2020) · Clinical & Experimental Immunology · doi:10.1111/cei.13561 · Cited by 27

Novel Forms of Immunomodulation for Cancer Therapy

del Valle, A. S., Naval, J., Anel, A., & Marzo, I. (2020) · Trends in cancer · doi:10.1016/j.trecan.2020.02.015 · Cited by 25

Immunotherapeutic advances in gastrointestinal malignancies

Rao, D., Parakrama, R. Y., Augustine, T. A., Liu, Q., Goel, S., & Maitra, R. (2019) · npj Precision Oncology · doi:10.1038/s41698-018-0076-8 · Cited by 25

Association of Tim-3/Gal-9 Axis with NLRC4 Inflammasome in Glioma Malignancy: Tim-3/Gal-9 Induce the NLRC4 Inflammasome

Sim, J., Park, J., Kim, S., Hwang, S., Sung, K., Lee, J.-E., Yang, S.-H., Cho, K. G., Lee, S. H., Moon, J., et al. (2022) · International Journal of Molecular Sciences · doi:10.3390/ijms23042028 · Cited by 24

Exosomal cargoes in OSCC: current findings and potential functions

Zhao, C., Zhang, G., Liu, J., Zhang, C., Yao, Y., & Liao, W. (2020) · PeerJ · doi:10.7717/peerj.10062 · Cited by 24

Clinicopathological Features of Gastric Cancer with Autoimmune Gastritis

Arai, J., Niikura, R., Hayakawa, Y., Suzuki, N., Hirata, Y., Ushiku, T., & Fujishiro, M. (2022) · Biomedicines · doi:10.3390/biomedicines10040884 · Cited by 23

Profiling networks of distinct immune-cells in tumors

Clancy, T., & Hovig, E. J. (2016) · BMC Bioinformatics · doi:10.1186/s12859-016-1141-3 · Cited by 22

Tumor immunotherapy: drug-induced neoantigens (xenogenization) and immune checkpoint inhibitors

Franzese, O., Torino, F., Fuggetta, M. P., Aquino, A., Roselli, M., Bonmassar, E., Giuliani, A., & D’Atri, S. (2017) · Oncotarget · doi:10.18632/oncotarget.16335 · Cited by 23

Nanomedicine-Mediated Optimization of Immunotherapeutic Approaches in Cervical Cancer

Venkatas, J., & Singh, M. (2021) · Nanomedicine · doi:10.2217/nnm-2021-0044 · Cited by 25

Marine Alkaloids: Compounds with In Vivo Activity and Chemical Synthesis

Munekata, P. E. S., Pateiro, M., Conte‐Júnior, C. A., Domínguez, R., Nawaz, A., Walayat, N., Fierro, E. M., & Lorenzo, J. M. (2021) · Marine Drugs · doi:10.3390/md19070374 · Cited by 23

Immodin and its immune system supportive role in paclitaxel therapy of 4T1 mouse breast cancer

Demečková, V., Solár, P., Hrčková, G., Mudroňová, D., Bojková, B., Kassayová, M., & Gancarčíková, S. (2017) · Biomedicine & Pharmacotherapy · doi:10.1016/j.biopha.2017.02.034 · Cited by 23

Have Cells Harboring the HIV Reservoir Been Immunoedited?

Huang, S.-H., McCann, C. D., Mota, T. M., Wang, C., Lipkin, S. M., & Jones, R. B. (2019) · Frontiers in Immunology · doi:10.3389/fimmu.2019.01842 · Cited by 23

Differential Expression and Clinicopathological Significance of HER2, Indoleamine 2,3-Dioxygenase and PD-L1 in Urothelial Carcinoma of the Bladder

Kim, D., Kim, J., Kim, J.-S., Kim, S., & Kim, K. (2020) · Journal of Clinical Medicine · doi:10.3390/jcm9051265 · Cited by 22

Human leukocyte antigen‑G expression and polymorphisms promote cancer development and guide cancer diagnosis/treatment (Review)

Zhang, Y., Yu, S., Han, Y., Wang, Y., & Sun, Y. (2017) · Oncology Letters · doi:10.3892/ol.2017.7407 · Cited by 21

Overexpression of Murine Rnaset2 in a Colon Syngeneic Mouse Carcinoma Model Leads to Rebalance of Intra-Tumor M1/M2 Macrophage Ratio, Activation of T Cells, Delayed Tumor Growth, and Rejection

Vito, A. D., Orecchia, P., Balza, E., Reverberi, D., Scaldaferri, D., Taramelli, R., Noonan, D. M., Acquati, F., & Mortara, L. (2020) · Cancers · doi:10.3390/cancers12030717 · Cited by 21

Pediatric Brain Tumours: Lessons from the Immune Microenvironment

Yao, B., Delaidelli, A., Vogel, H. S., & Sorensen, P. H. B. (2023) · Current Oncology · doi:10.3390/curroncol30050379 · Cited by 21

Immune Checkpoint Inhibitors and Infection: What Is the Interplay?

Papadakis, M., Karniadakis, I., Mazonakis, N., Akinosoglou, K., Tsioutis, C., & Spernovasilis, N. A. (2023) · In Vivo · doi:10.21873/invivo.13346 · Cited by 21

Cancer as an ecomolecular disease and a neoplastic consortium

y Cajal, S. R., Capdevila, C., Hernández‐Losa, J., Mattos‐Arruda, L. D., Ghosh, A., Lorent, J., Larsson, O. S., Aasen, T., Postovit, L.-M. M., & Topisirović, I. (2017) · Biochimica et Biophysica Acta (BBA) - Reviews on Cancer · doi:10.1016/j.bbcan.2017.09.004 · Cited by 20

Enhancing tumor specific immune responses by transcutaneous vaccination

Saliba, H., Heurtault, B., Bouharoun‐Tayoun, H., Flacher, V., Frisch, B., Fournel, S., & Chamat, S. (2017) · Expert Review of Vaccines · doi:10.1080/14760584.2017.1382357 · Cited by 20

Novel human immunomodulatory T cell receptors and their double-edged potential in autoimmunity, cardiovascular disease and cancer

Martı́n, P., Blanco-Domínguez, R., & Sánchez‐Díaz, R. (2020) · Cellular and Molecular Immunology · doi:10.1038/s41423-020-00586-4 · Cited by 18

Four Immune-Related Long Non-coding RNAs for Prognosis Prediction in Patients With Hepatocellular Carcinoma

Li, M., Liang, M., Lan, T., Wu, X., Xie, W., Wang, T., Chen, Z., Shen, S., & Peng, B. (2020) · Frontiers in Molecular Biosciences · doi:10.3389/fmolb.2020.566491 · Cited by 19

Antiproliferative, Antiangiogenic, and Antimetastatic Therapy Response by Mangiferin in a Syngeneic Immunocompetent Colorectal Cancer Mouse Model Involves Changes in Mitochondrial Energy Metabolism

Rodriguez-Gonzalez, J. C., Hernández-Balmaseda, I., Declerck, K., Pérez-Novo, C., Logie, E., Theys, C., Jakubek, P., Quiñones-Maza, O. L., Dantas-Cassali, G., Carlos dos Reis, D., et al. (2021) · Frontiers in Pharmacology · doi:10.3389/fphar.2021.670167 · Cited by 19

Unlocking the potential of the tumor microenvironment for cancer therapy

Tufail, M. (2023) · Pathology - Research and Practice · doi:10.1016/j.prp.2023.154846 · Cited by 20

Immunotherapy Innovations in the Fight against Osteosarcoma: Emerging Strategies and Promising Progress

Cheng, S., Wang, H., Kang, X., & Zhang, H. (2024) · Pharmaceutics · doi:10.3390/pharmaceutics16020251 · Cited by 19

Daunting but Worthy Goal

Dantal, J., & Campone, M. (2016) · Transplantation · doi:10.1097/tp.0000000000001428 · Cited by 20

Integrative Bioinformatics Approaches to Screen Potential Prognostic Immune-Related Genes and Drugs in the Cervical Cancer Microenvironment

Zhao, Z., Li, J., Li, H., Wu, N., Ouyang, P., Liu, S., Cai, J., & Wang, J. (2020) · Frontiers in Genetics · doi:10.3389/fgene.2020.00727 · Cited by 19

FcγRIIB potentiates differentiation of myeloid-derived suppressor cells to mediate tumor immunoescape

Wu, L., Xu, Y., Zhao, H., Zhou, Y. J., Chen, Y., Yang, S., Lei, J., Zhang, J., Wang, J., Wu, Y., et al. (2021) · Theranostics · doi:10.7150/thno.66575 · Cited by 18

Epigenetic reprogramming of T cells: unlocking new avenues for cancer immunotherapy

Singh, V., Nandi, S., Ghosh, A., Adhikary, S., Mukherjee, S., Roy, S., & Das, C. (2024) · Cancer and Metastasis Reviews · doi:10.1007/s10555-024-10167-w · Cited by 21

Intercepting Premalignant, Preinvasive Breast Lesions Through Vaccination

Zachariah, N. N., Basu, A. B., Gautam, N., Ramamoorthi, G., Kodumudi, K. N., Kumar, N. B., Loftus, L., & Czerniecki, B. J. (2021) · Frontiers in Immunology · doi:10.3389/fimmu.2021.786286 · Cited by 18

Chitosan-Based Nanoparticles for Intracellular Delivery of ISAV Fusion Protein cDNA into Melanoma Cells: A Path to Develop Oncolytic Anticancer Therapies

Robles-Planells, C., Sánchez-Guerrero, G., Barrera‐Avalos, C., Matiacevich, S., Rojo, L. E., Pavez, J., Salas‐Huenuleo, E., Kogan, M. J., Escobar, A. F., Milla, L. A., et al. (2020) · Mediators of Inflammation · doi:10.1155/2020/8680692 · Cited by 17

Advances in technology and applications of nanoimmunotherapy for cancer

Dou, L., Meng, X., Yang, H., & Dong, H. (2021) · Biomarker Research · doi:10.1186/s40364-021-00321-9 · Cited by 18

Systemic CD4 Immunity and PD-L1/PD-1 Blockade Immunotherapy

Escors, D., Bocanegra, A., Chocarro, L., Blanco, E., Piñeiro‐Hermida, S., Garnica, M., Fernández, L., Vera, R., Arasanz, H., & Kochan, G. T. (2022) · International Journal of Molecular Sciences · doi:10.3390/ijms232113241 · Cited by 18

Immunoregulatory Potential of Exosomes Derived from Cancer Stem Cells

Clayton, S. M., Archard, J. A., Wagner, J., Farwell, D. G., Bewley, A., Beliveau, A. M., Birkeland, A., Rao, S. S., Abouyared, M., Belafsky, P. C., et al. (2019) · Stem Cells and Development · doi:10.1089/scd.2019.0197 · Cited by 17

Advances in Tumor Organoids for the Evaluation of Drugs: A Bibliographic Review

Londoño-Berrío, M., Castro, C. I., Cañas, A. I., Ortiz, I., & Osorio, M. (2022) · Pharmaceutics · doi:10.3390/pharmaceutics14122709 · Cited by 16

Tumor-Infiltrating B Lymphocytes: Promising Immunotherapeutic Targets for Primary Liver Cancer Treatment

Milardi, G., & Lleò, A. (2023) · Cancers · doi:10.3390/cancers15072182 · Cited by 16

Visualized photodynamic nanomaterials activating tumor-associated immune landscape as a next-generation anticancer strategy

Tian, L., Li, X., Guo, L., Huang, L., Wu, X., & Gao, W. (2024) · Coordination Chemistry Reviews · doi:10.1016/j.ccr.2024.216027 · Cited by 16

A mechanism for evasion of CTL immunity by altered O -glycosylation of HLA class I

Yoneyama, M. S., Tobisawa, Y., Hatakeyama, S., Sato, M., Tone, K., Tatara, Y., Kakizaki, I., Funyu, T., Fukuda, M., Hoshi, S., et al. (2016) · The Journal of Biochemistry · doi:10.1093/jb/mvw096 · Cited by 16

EBV ‐positive pyothorax‐associated lymphoma expresses CXCL9 and CXCL10 chemokines that attract cytotoxic lymphocytes via CXCR3

Higuchi, T., Hashida, Y., Matsuo, K., Kitahata, K., Ujihara, T., Murakami, I., Nakayama, T., & Daibata, M. (2023) · Cancer Science · doi:10.1111/cas.15782 · Cited by 15

Advancements and hurdles in the development of a vaccine for triple-negative breast cancer: A comprehensive review of multi-omics and immunomics strategies

Dhanushkumar, T., E, S. M., Selvam, P. K., Rambabu, M., Dasegowda, K. R., Vasudevan, K., & Doss, C. G. P. (2023) · Life Sciences · doi:10.1016/j.lfs.2023.122360 · Cited by 16

The role of extracellular vesicles in cancer

Hurtado, E. C. P., Agudelo, J. S. H., da Silva, R. A., Viração, T. A., & Fernandes, C. J. D. C. (2024) · Current topics in membranes · doi:10.1016/bs.ctm.2024.06.010 · Cited by 17

Not Only Immune Escape—The Confusing Role of the TRP Metabolic Pathway in Carcinogenesis

Kwiatkowska, I., Hermanowicz, J. M., Przybyszewska-Podstawka, A., & Pawlak, D. (2021) · Cancers · doi:10.3390/cancers13112667 · Cited by 15

Immunomodulation: An immune regulatory mechanism in carcinoma therapeutics

Alsaffar, R. M., Ali, S., Rashid, S., Rashid, S. M., Majid, S., & Rehman, M. U. (2021) · International Immunopharmacology · doi:10.1016/j.intimp.2021.107984 · Cited by 16

Anti-Gr-1 Antibody Provides Short-Term Depletion of MDSC in Lymphodepleted Mice with Active-Specific Melanoma Therapy

Rose, P., van den Engel, N. K., Kovács, J., Hatz, R. A., Boon, L., & Winter, H. (2022) · Vaccines · doi:10.3390/vaccines10040560 · Cited by 17

Pancreatic Cancers with High Grade Tumor Budding Exhibit Hallmarks of Diminished Anti-Tumor Immunity

Sadozai, H., Acharjee, A., Gruber, T., Gloor, B., & Karamitopoulou, E. (2021) · Cancers · doi:10.3390/cancers13051090 · Cited by 14

Tumor-Associated Macrophages—Implications for Molecular Oncology and Imaging

Kimm, M. A., Klenk, C., Alunni‐Fabbroni, M., Kästle, S., Stechele, M., Ricke, J., Eisenblätter, M., & Wildgruber, M. (2021) · Biomedicines · doi:10.3390/biomedicines9040374 · Cited by 16

Collagen-Anchored Interleukin-2 and Interleukin-12 Safely Reprogram the Tumor Microenvironment in Canine Soft-Tissue Sarcomas

Stinson, J. A., Sheen, A. M., Momin, N., Hampel, J., Bernstein, R., Kamerer, R. L., Fadl-Alla, B. A., Samuelson, J., Fink, E., Fan, T. M., et al. (2023) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-23-0006 · Cited by 15

Application of Cyclodextrin for Cancer Immunotherapy

Wei, X., Yu, C., & Wei, H. (2023) · Molecules · doi:10.3390/molecules28145610 · Cited by 14

PD-1 blockade at the time of tumor escape potentiates the immune-mediated antitumor effects of a melanoma-targeting monoclonal antibody

They, L., Michaud, H., Becquart, O., Lafont, V., Guillot, B., Boissière‐Michot, F., Jarlier, M., Mollévi, C., Eliaou, J., Bonnefoy, N., et al. (2017) · OncoImmunology · doi:10.1080/2162402x.2017.1353857 · Cited by 14

Oxidative Stress in the Tumor Immune Microenvironment: Mechanisms and Therapeutic Perspectives

Wang, Z., Li, B., Tang, P., Yan, F., Wang, S., Leng, G., Dawa, P., Chen, Y., Guo, Y., Yang, P., et al. (2026) · MedComm – Oncology · doi:10.1002/mog2.70068 · Cited by 14

Role of lymphocytes, macrophages and immune receptors in suppression of tumor immunity

Singh, A., Anang, V., Kumari, K., Kottarath, S. K., & Verma, C. (2022) · Progress in molecular biology and translational science · doi:10.1016/bs.pmbts.2022.10.002 · Cited by 14

Innate lymphoid cells in early tumor development

Warner, K., Ghaedi, M., Chung, D. C., Jacquelot, N., & Ohashi, P. S. (2022) · Frontiers in Immunology · doi:10.3389/fimmu.2022.948358 · Cited by 13

Antitumoral and Immunomodulatory Effect of Mahonia aquifolium Extracts

Andreicuț, A. D., Fischer‐Fodor, E., Pârvu, A. E., Țigu, A. B., Cenariu, M., Pârvu, M., Cătoi, A. F., & Irimie, A. (2019) · Oxidative Medicine and Cellular Longevity · doi:10.1155/2019/6439021 · Cited by 16

Sarcoidosis-like disease mimicking metastases during adjuvant ipilimumab therapy in advanced melanoma patient: CT scan and MRI help in managing difficult clinical decision

Garanzini, E. M., Scaramuzza, D., Spadarella, G., Guardo, L. D., & Marchianò, A. V. (2020) · BJR|case reports · doi:10.1259/bjrcr.20190065 · Cited by 14

Liquid Biopsy to Detect DNA/RNA Based Markers of Small DNA Oncogenic Viruses for Prostate Cancer Diagnosis, Prognosis, and Prediction

Provenzano, M., & Allayeh, A. K. (2020) · Frontiers in Oncology · doi:10.3389/fonc.2020.00778 · Cited by 13

Low Piperine Fractional Piper nigrum Extract Enhanced the Antitumor Immunity via Regulating the Th1/Th2/Treg Cell Subsets on NMU-Induced Tumorigenesis Rats

Saetang, J., Tedasen, A., Sangkhathat, S., Sangkaew, N., Dokduang, S., Prompat, N., Taraporn, S., & Graidist, P. (2021) · Planta Medica · doi:10.1055/a-1458-5646 · Cited by 13

New insights on ‘old’ toxicants in occupational toxicology

Costa, C., Miozzi, E., Teodoro, M., Briguglio, G., Rapisarda, V., & Fenga, C. (2017) · Molecular Medicine Reports · doi:10.3892/mmr.2017.6374 · Cited by 12

The attenuation effect of low piperine Piper nigrum extract on doxorubicin-induced toxicity of blood chemical and immunological properties in mammary tumour rats

Saetang, J., Tedasen, A., Sangkhathat, S., Sangkaew, N., Dokduang, S., Prompat, N., Taraporn, S., & Graidist, P. (2021) · Pharmaceutical Biology · doi:10.1080/13880209.2021.2018470 · Cited by 13

Dynamic changes in the systemic immune-inflammation index predict the prognosis of EGFR-mutant lung adenocarcinoma patients receiving brain metastasis radiotherapy

Wang, Q., Tan, X., Deng, G., Fu, S., Li, J., & Li, Z. (2022) · BMC Pulmonary Medicine · doi:10.1186/s12890-022-01866-7 · Cited by 13

Cancer Immunoprevention and Public Health

Singh, S. K., & Dorak, M. T. (2017) · Frontiers in Public Health · doi:10.3389/fpubh.2017.00101 · Cited by 13

Xanthomicrol Exerts Antiangiogenic and Antitumor Effects in a Mouse Melanoma (B16F10) Allograft Model

Ghazizadeh, F., Shafiei, M., Falak, R., Panahi, M., Rakhshani, N., Ebrahimi, S. A., & Rahimi‐Moghaddam, P. (2020) · Evidence-based Complementary and Alternative Medicine · doi:10.1155/2020/8543872 · Cited by 12

Basics of immunotherapy for epithelial ovarian cancer

Collin-Bund, V., Azaïs, H., Bibi‐Triki, S., Lecointre, L., Bétrian, S., Ángeles, M. A., Eberst, L., Faller, É., Boisramé, T., Bendifallah, S., et al. (2021) · Journal of Gynecology Obstetrics and Human Reproduction · doi:10.1016/j.jogoh.2021.102283 · Cited by 11

Overview of Basic Immunology and Clinical Application

Stephen, B., & Hajjar, J. (2020) · Advances in experimental medicine and biology · doi:10.1007/978-3-030-41008-7_1 · Cited by 11

An Angiogenesis-Related lncRNA Signature Is Associated with Prognosis and Tumor Immune Microenvironment in Breast Cancer

Gao, S., Wang, Y., Xu, Y., & Liu, S. (2023) · Journal of Personalized Medicine · doi:10.3390/jpm13030513 · Cited by 10

Localized Nano-mediated Interleukin-12 Gene Therapy: Promising Candidate for Cancer Immunotherapeutics

Singh, M., & Venkatas, J. (2022) · Current Cancer Drug Targets · doi:10.2174/1568009622666220609115109 · Cited by 9

Perioperative corticosteroid treatment impairs tumor-infiltrating dendritic cells in patients with newly diagnosed adult-type diffuse gliomas

Carenza, C., Franzese, S., Castagna, A., Terzoli, S., Simonelli, M., Persico, P., Bello, L., Nibali, M. C., Pessina, F., Kunderfranco, P., et al. (2023) · Frontiers in Immunology · doi:10.3389/fimmu.2022.1074762 · Cited by 11

Comprehensive Phenotyping of Dendritic Cells in Cancer Patients by Flow Cytometry

Carenza, C., Franzese, S., Calcaterra, F., Mavilio, D., & Bella, S. D. (2020) · Cytometry Part A · doi:10.1002/cyto.a.24245 · Cited by 10

Role of immune system in TNBC

Mir, M. A., Sofi, S., & Qayoom, H. (2022) · Elsevier eBooks · doi:10.1016/b978-0-323-96136-3.00014-5 · Cited by 9

The crosstalk between nerves and immunity: chronic stress as a driver of tumor progression

He, Y., Yu, H., Li, F., Liu, J., Chen, Z., Zhu, W., Yang, L., & Yan, T. (2026) · Frontiers in Immunology · doi:10.3389/fimmu.2026.1758894 · Cited by 12

Scientific and clinical implications of genetic and cellular heterogeneity in uveal melanoma

de Lange, M. J., Nell, R. J., & van der Velden, P. A. (2021) · Molecular Biomedicine · doi:10.1186/s43556-021-00048-x · Cited by 9

New insight into cancer immunotherapy

Escribese, M. M., & Barber, D. (2017) · Allergologia et Immunopathologia · doi:10.1016/j.aller.2017.09.013 · Cited by 9

Reversing cancer immunoediting phases with a tumor-activated and optically reinforced immunoscaffold

Li, X., Liang, X., Fu, W., Luo, R., Zhang, M., Kou, X., Zhang, Y., Li, Y., Huang, D., You, Y., et al. (2024) · Bioactive Materials · doi:10.1016/j.bioactmat.2024.01.026 · Cited by 8

Natural Innate and Adaptive Immunity to Cancer

Vesely, M. D., Kershaw, M. H., Schreiber, R. D., & Smyth, M. J. (2011) · Annual Review of Immunology · doi:10.1146/annurev-immunol-031210-101324 · Cited by 2,225

Cancer immunoediting and resistance to T cell-based immunotherapy

O’Donnell, J. S., Teng, M. W. L., & Smyth, M. J. (2018) · Nature Reviews Clinical Oncology · doi:10.1038/s41571-018-0142-8 · Cited by 1,826

Cancer Immunoediting in the Era of Immuno-oncology

Gubin, M. M., & Vesely, M. D. (2022) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-21-1804 · Cited by 161

Progress on cancer immunoediting

Zhou, Y., Gong, H., & Yu, F. G. (2009) · Int J Immunol · doi:10.3760/cma.j.issn.1673-4394.2009.04.019

Cancer immunoediting: antigens, mechanisms, and implications to cancer immunotherapy

Vesely, M. D., & Schreiber, R. D. (2013) · Annals of the New York Academy of Sciences · doi:10.1111/nyas.12105 · Cited by 367